Intellia Therapeutics Inc. (NTLA)
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 200-day moving average, which suggests a long-term bullish trend.
Intellia Stock Declines Around 55% in 3 Months: Here's Why
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $1.34 per share a year ago.
